TABLE 3.

Studies of active targeting nanoparticles for multiple myeloma

Targets	Types	Agents	Injection method	In vivo model	Refs.
CD38	Liposome	Doxorubicin	iv	NCI‐H929 subcutaneous model	178
Bone/transferrin receptor	Liposome	Paclitaxel	ip	MM.1S orthotopic model	179
P‐selectin	Liposome	Bortezomib/Y27632	iv	MM.1S orthotopic model	181
CD3/BCMA, CS1, CD38	Liposomal multispecific T‐cell engager	–	iv	MM.1S orthotopic model	183
CD44	Core‐disulfide‐crosslinked micelle	Carfilzomib	iv	LP‐1 subcutaneous model	185
VLA‐4	Micelle	Camptothecin prodrug	iv	5TGM1 orthotopic model	186
CD44	Hyaluronic acid‐shelled and core‐disulfide‐crosslinked micelle	Bortezomib	iv	LP‐1 subcutaneous model	192
CD44	Lipoic acid‐crosslinked hyaluronic acid nanoparticle	Doxorubicin	iv	LP‐1 subcutaneous model	190
CD44	Polymersome	Epirubicin	iv	LP‐1 orthotopic model	194
CD44	Chimeric polymersome	Granzyme B	iv	LP‐1 subcutaneous/orthotopic model	195
CD38	Immunopolymersome	Vincristine sulfate	iv	LP‐1 orthotopic model	196
CD38	Chitosan nanoparticle	Bortezomib	iv	MM.1S orthotopic model	197
CD38	Polymeric nanoparticle	S3I‐1757	iv	U266 orthotopic model	198
Bone	Polymeric nanoparticle	Bortezomib	ip	MM.1S orthotopic model	200
Bone marrow/transferrin receptor	Titanium dioxide nanoparticle	89Zr	iv	MM.1S orthotopic model	209
Bone/CD44	Platelet membrane‐coated nanoparticle	Bortezomib/tPA	iv	NCI‐H929 orthotopic model	221
Bone marrow	MM cell membrane‐coated nanoparticle	Bortezomib	iv	MRD orthotopic model	222

Abbreviations. ip, intraperitoneal injection; iv, intravenous injection.